Genetically modified cell membrane proteins in tissue engineering and regenerative medicine
Source abstract
Abstract
Abstract Genetically modified cell membrane proteins can effectively regulate cell proliferation and differentiation, while also integrating novel biomaterials. As a promising biomedical tool, this technology has broad applications in tissue engineering and regenerative medicine. Both viral and non-viral gene transfection methods have been employed to create genetically modified cell membrane proteins. Numerous studies have demonstrated the significant efficacy of genetically modified cell membrane proteins in promoting bone regeneration, treating cardiovascular diseases, aiding lung injury recovery, advancing immunotherapy, and in applications involving engineered cell membrane sheets and cell spheroids. However, this technology faces several limitations, including biosafety and ethical concerns associated with genetic modification. This article summarizes recent advances in genetically modified cell membrane proteins, detailing their preparation, applications, limitations, and future directions.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Virus-based gene therapy research · Tissue Engineering and Regenerative Medicine
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Cell sheet composed of adipose-derived stem cells demonstrates enhanced skin wound healing with reduced scar formation10.1016/j.actbio.2018.07.022 ↗
2. Genetically engineered cell membrane-coated nanoparticles with high-density customized membrane receptor for high-performance drug lead discovery10.1021/acsami.3c10907 ↗
3. Genetically modified cell spheroids for tissue engineering and regenerative medicine10.1016/j.jconrel.2023.01.033 ↗
4. Nanostructured materials for dental tissue engineering
5. Genetically-modified stem cell in regenerative medicine and cancer therapy; a new era10.2174/1566523221666210707125342 ↗
6. A modular approach to enhancing cell membrane-coated nanoparticle functionality using genetic engineering10.1038/s41565-023-01533-w ↗
7. Sequential genome-wide CRISPR-Cas9 screens identify genes regulating cell-surface expression of tetraspanins10.1016/j.celrep.2023.112065 ↗
8. Genetically engineered-cell-membrane nanovesicles for cancer immunotherapy10.1002/advs.202302131 ↗
9. Genetically targeted chemical assembly of polymers specifically localized extracellularly to surface membranes of living neurons10.1126/sciadv.adi1870 ↗
10. Graphene-based material-mediated immunomodulation in tissue engineering and regeneration: mechanism and significance10.1021/acsnano.3c03857 ↗
11. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection10.1073/pnas.91.23.11153 ↗
12. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics10.1038/83324 ↗
13. Efficient transfection of embryonic and adult stem cells10.1634/stemcells.22-4-531 ↗
14. Local gene delivery for cancer therapy10.2174/156652311797415854 ↗
15. Fast and efficient generation of knock-in human organoids using homology-independent CRISPR-Cas9 precision genome editing10.1038/s41556-020-0472-5 ↗
16. Graft dysfunction in compassionate use of genetically engineered pig-to-human cardiac xenotransplantation: a case report10.1016/S0140-6736(23)00775-4 ↗
17. EGFR-conjugated hydrogel accelerates wound healing on ulcer-induced burn wounds by targeting collagen and inflammatory cells using photoimmunomodulatory inhibition10.1016/j.msec.2020.111541 ↗
18. CCR2-engineered mesenchymal stromal cells accelerate diabetic wound healing by restoring immunological homeostasis10.1016/j.biomaterials.2021.120963 ↗
19. Lentivirus-mediated silencing of P75 neurotrophin receptor combined with nerve growth factor overexpression and transfection of bone marrow mesenchymal stem cells combined with demineralized bone matrix for heterotopic osteogenesis10.7507/1002-1892.202003166 ↗
20. p75NTR optimizes the osteogenic potential of human periodontal ligament stem cells by up-regulating α1 integrin expression10.1111/jcmm.15390 ↗
21. Mesenchymal stem cells injected into carotid artery to target focal brain injury home to perivascular space10.7150/thno.43169 ↗
22. Intra-bone bone marrow transplantation from hCD47 transgenic pigs to baboons prolongs chimerism to >60 days and promotes increased porcine lung transplant survival10.1111/xen.12552 ↗
23. Preclinical evaluation of CAR T cell function: in vitro and in vivo models10.3390/ijms23063154 ↗
24. Preclinical in vitro and in vivo models for adoptive cell therapy of cancer10.1097/PPO.0000000000000609 ↗
25. Tissue-engineered vascular microphysiological platform to study immune modulation of xenograft rejection10.1126/sciadv.abg2237 ↗
26. Genetically modified cell sheets in regenerative medicine and tissue engineering10.1016/j.biomaterials.2021.120908 ↗
27. Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines10.1073/pnas.2014352117 ↗
28. CAIX-specific CAR-T cells and sunitinib show synergistic effects against metastatic renal cancer models10.1097/CJI.0000000000000301 ↗
29. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma10.1186/s13046-021-02214-z ↗
30. CD38-specific CAR integrated into CD38 locus driven by different promoters causes distinct antitumor activities of T and NK cells10.1002/advs.202207394 ↗
31. In situ repurposing of dendritic cells with CRISPR/Cas9-based nanomedicine to induce transplant tolerance10.1016/j.biomaterials.2019.119302 ↗
32. Engineered exosomes containing microRNA-29b-2 and targeting the somatostatin receptor reduce presenilin 1 expression and decrease the β-amyloid accumulation in the brains of mice with Alzheimer’s disease10.2147/IJN.S442876 ↗
33. Role of human CD200 overexpression in pig-to-human xenogeneic immune response compared with human CD47 overexpression10.1097/TP.0000000000001966 ↗
34. Mononuclear phagocyte system blockade using extracellular vesicles modified with CD47 on membrane surface for myocardial infarction reperfusion injury treatment10.1016/j.biomaterials.2021.121000 ↗
35. CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity10.1038/s41467-019-12321-3 ↗
36. CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy10.1038/s41467-023-37872-4 ↗
37. LunX-CAR T cells as a targeted therapy for non-small cell lung cancer10.1016/j.omto.2020.04.008 ↗
38. Genetically edited T-cell membrane coated AIEgen nanoparticles effectively prevents glioblastoma recurrence10.1016/j.biomaterials.2022.121981 ↗
39. Genetically engineered cell-derived nanoparticles for targeted breast cancer immunotherapy10.1016/j.ymthe.2019.11.020 ↗
40. HER2-targeting CAR-T cells show highly efficient anti-tumor activity against glioblastoma both in vitro and in vivo10.1038/s41435-024-00275-6 ↗
41. Overexpression of ERBB4 rejuvenates aged mesenchymal stem cells and enhances angiogenesis via PI3K/AKT and MAPK/ERK pathways10.1096/fj.201801690R ↗
42. Inhibition of TGFβ1 activation prevents radiation-induced lung fibrosis10.1002/ctm2.1546 ↗
43. Overexpression of α5β1 integrin and angiopoietin-1 co-operatively promote blood-brain barrier integrity and angiogenesis following ischemic stroke10.1016/j.expneurol.2019.113042 ↗
44. Genetically engineered cell membrane-coated nanoparticles for targeted delivery of dexamethasone to inflamed lungs10.1126/sciadv.abf7820 ↗
45. Overexpression of integrin β(2) improves migration and engraftment of adipose-derived stem cells and augments angiogenesis in myocardial infarction10.21037/atm-22-3339 ↗
46. Protective effect of MAPK signaling pathway mediated by ITGB3 gene silencing on myocardial ischemia-reperfusion injury in mice and its mechanism10.26355/eurrev_202101_24647 ↗
47. KLRC1 knockout overcomes HLA-E-mediated inhibition and improves NK cell antitumor activity against solid tumors10.3389/fimmu.2023.1231916 ↗
48. LRP5 regulates cardiomyocyte proliferation and neonatal heart regeneration by the AKT/P21 pathway10.1111/jcmm.17311 ↗
49. Overexpression of Lrp5 enhanced the anti-breast cancer effects of osteocytes in bone10.1038/s41413-021-00152-2 ↗
50. An effective light activated TiO2 nanodot platform for gene delivery within cell sheets to enhance osseointegration10.1016/j.cej.2020.126170 ↗
51. Downregulated low-density lipoprotein receptor-related protein 6 induces the maldevelopment of extravillous trophoblast via Wnt/β-catenin signaling pathway10.1016/j.mcp.2019.01.004 ↗
52. PD-1 blockade cellular vesicles for cancer immunotherapy10.1002/adma.201707112 ↗
53. Engineering PD-1-presenting platelets for cancer immunotherapy10.1021/acs.nanolett.8b02321 ↗
54. PD-1 mediates microglia polarization via the MAPK signaling pathway to protect blood-brain barrier function during cerebral ischemia/reperfusion10.1016/j.brainresbull.2024.111055 ↗
55. Toll-like receptor 2 signaling deficiency in cardiac cells ameliorates Ang II-induced cardiac inflammation and remodeling10.1016/j.trsl.2021.02.011 ↗
56. TNF receptor 2 knockout mouse had reduced lung cancer growth and schizophrenia-like behavior through a decrease in TrkB-dependent BDNF level10.1007/s12272-024-01487-0 ↗
57. Introduction of tenomodulin by gene transfection vectors for rat bone tissue regeneration10.1016/j.reth.2022.12.008 ↗
58. Inhibition of TREM1 reduces inflammation and oxidative stress after spinal cord injury (SCI) associated with HO-1 expressions10.1016/j.biopha.2018.08.159 ↗
59. Vision protection and robust axon regeneration in glaucoma models by membrane-associated Trk receptors10.1016/j.ymthe.2022.11.018 ↗
60. Using genetically modified extracellular vesicles as a non-invasive strategy to evaluate brain-specific cargo10.1016/j.biomaterials.2022.121366 ↗
61. Claudin18.2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer10.1093/jnci/djy134 ↗
62. Connexin43 overexpression promotes bone regeneration by osteogenesis and angiogenesis in rat glucocorticoid-induced osteonecrosis of the femoral head10.1016/j.ydbio.2023.02.004 ↗
63. Modeling reentry in the short QT syndrome with human-induced pluripotent stem cell-derived cardiac cell sheets10.1016/j.jacc.2019.02.055 ↗
64. Overexpression of CXCR7 promotes mesenchymal stem cells to repair phosgene-induced acute lung injury in rats10.1016/j.biopha.2018.10.108 ↗
65. Upregulating CXCR7 accelerates endothelial progenitor cell-mediated endothelial repair by activating Akt/Keap-1/Nrf2 signaling in diabetes mellitus10.1186/s13287-021-02324-7 ↗
66. Targeted homing of CCR2-overexpressing mesenchymal stromal cells to ischemic brain enhances post-stroke recovery partially through PRDX4-mediated blood-brain barrier preservation10.7150/thno.28029 ↗
67. CCR2-overexpressing mesenchymal stem cells targeting damaged liver enhance recovery of acute liver failure10.1186/s13287-022-02729-y ↗
68. Genetically engineered macrophages co-loaded with CD47 inhibitors synergistically reconstruct efferocytosis and improve cardiac remodeling post myocardial ischemia reperfusion injury10.1002/adhm.202303267 ↗
69. Silencing Celsr2 inhibits the proliferation and migration of Schwann cells through suppressing the Wnt/β-catenin signaling pathway10.1016/j.bbrc.2020.09.015 ↗
70. CXCR3A promotes the secretion of the antifibrotic decoy receptor sIL-13Rα2 by pulmonary fibroblasts10.1152/ajpcell.00076.2020 ↗
71. Enhanced migration and immunoregulatory capacity of BMSCs mediated by overexpression of CXCR4 and IL-3510.1016/j.molimm.2022.07.005 ↗
72. Transfection with CXCR4 potentiates homing of mesenchymal stem cells in vitro and therapy of diabetic retinopathy in vivo10.18240/ijo.2018.05.08 ↗
73. Targeted drug delivery to stroke via chemotactic recruitment of nanoparticles coated with membrane of engineered neural stem cells10.1002/smll.201902011 ↗
74. CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3/NF-κB/SDF-1α axis to enhance efficacy against pancreatic cancer10.1016/j.ymthe.2023.09.010 ↗
75. Exosome-guided bone targeted delivery of Antagomir-188 as an anabolic therapy for bone loss10.1016/j.bioactmat.2021.02.014 ↗
76. CXCR4-overexpressing umbilical cord mesenchymal stem cells enhance protection against radiation-induced lung injury10.1155/2019/2457082 ↗
77. Genetically engineered CXCR4-modified exosomes for delivery of miR-126 mimics to macrophages alleviate periodontitis10.1186/s12951-023-01863-w ↗
78. Bioengineered stem cell membrane functionalized nanocarriers for therapeutic targeting of severe hindlimb ischemia10.1016/j.biomaterials.2018.08.018 ↗
79. CXCR4 uses STAT3-mediated slug expression to maintain radioresistance of non-small cell lung cancer cells: emerges as a potential prognostic biomarker for lung cancer10.1038/s41419-020-03280-5 ↗
80. Cxcr6-based mesenchymal stem cell gene therapy potentiates skin regeneration in murine diabetic wounds10.1016/j.ymthe.2020.02.014 ↗
81. Lgr4 governs a pro-inflammatory program in macrophages to antagonize post-infarction cardiac repair10.1161/CIRCRESAHA.119.315807 ↗
82. Lgr5-overexpressing mesenchymal stem cells augment fracture healing through regulation of Wnt/ERK signaling pathways and mitochondrial dynamics10.1096/fj.201900082RR ↗
83. Down-regulation of LGR6 promotes bone fracture recovery using bone marrow stromal cells10.1016/j.biopha.2017.12.109 ↗
84. P-glycoprotein exacerbates brain injury following experimental cerebral ischemia by promoting proinflammatory microglia activation10.1155/2023/6916819 ↗
85. Transfection types, methods and strategies: a technical review10.7717/peerj.11165 ↗
86. Single-cell transfection technologies for cell therapies and gene editing10.1016/j.jconrel.2020.10.068 ↗
87. The significance of chemical transfection/transduction enhancers in promoting the viral vectors-assisted gene delivery approaches: a focus on potentials for inherited retinal diseases10.1016/j.ejbt.2024.07.005 ↗
88. Applications and developments of gene therapy drug delivery systems for genetic diseases10.1016/j.ajps.2021.05.003 ↗
89. Gene therapy: comprehensive overview and therapeutic applications10.1016/j.lfs.2022.120375 ↗
90. Evolving horizons: adenovirus vectors’ timeless influence on cancer, gene therapy and vaccines10.3390/v15122378 ↗
91. Adenoviral vector system: a comprehensive overview of constructions, therapeutic applications and host responses10.1007/s12275-024-00159-4 ↗
92. Strategies for modifying adenoviral vectors for gene therapy10.3390/ijms252212461 ↗
93. The effect of CXCR4 overexpression on mesenchymal stem cell transplantation in ischemic stroke10.3727/215517912X647172 ↗
94. Adenovirus vector system: construction, history and therapeutic applications10.2144/btn-2022-0051 ↗
95. High-capacity adenoviral vectors: expanding the scope of gene therapy10.3390/ijms21103643 ↗
96. Production of first generation adenovirus vectors: a review10.1038/sj.gt.3301301 ↗
97. Gutless adenovirus: last-generation adenovirus for gene therapy10.1038/sj.gt.3302612 ↗
98. Adenovirus-neutralizing and infection-promoting activities measured in serum of human brain cancer patients treated with oncolytic adenovirus Ad5-Δ24.RGD10.3390/ijms26020854 ↗
99. CRISPR/Cas9 systems: delivery technologies and biomedical applications10.1016/j.ajps.2023.100854 ↗
100. Production of CRISPR/Cas9-mediated self-cleaving helper-dependent adenoviruses10.1016/j.omtm.2019.04.003 ↗